Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Taoufik El Gnaoui"'
Autor:
Simon B. Gressens, Vincent Enouf, Antoine Créon, Giovanna Melica, Francois Lemonnier, Jehan Dupuis, Taoufik El Gnaoui, Mohammad Hammoud, Karim Belhadj, Corinne Haioun, Anne Le Bouter, Sebastien Gallien, Fabien Le Bras, Slim Fourati
Publikováno v:
International Journal of Infectious Diseases, Vol 146, Iss , Pp 107108- (2024)
Objectives: Daratumumab-treated myeloma patients may face increased seasonal influenza risk due to weakened postvaccination immune responses, especially with daratumumab treatment. We aimed to assess humoral responses to boosted influenza vaccination
Externí odkaz:
https://doaj.org/article/215aa9b424b74509aa568bf0a333cf7d
Autor:
Nicolas Mounier, Taoufik El Gnaoui, Hervé Tilly, Danièle Canioni, Catherine Sebban, René-Olivier Casasnovas, Richard Delarue, Anne Sonet, Pauline Beaussart, Tony Petrella, Sylvie Castaigne, Serge Bologna, Gilles Salles, Alain Rahmouni, Philippe Gaulard, Corinne Haioun
Publikováno v:
Haematologica, Vol 98, Iss 11 (2013)
A previous pilot study with rituximab, gemcitabine and oxaliplatin showed promising activity in patients with refractory/relapsed B-cell lymphoma. We, therefore, conducted a phase II study to determine whether these results could be reproduced in a m
Externí odkaz:
https://doaj.org/article/054a821271f04e3b922eb8f262a1b18d
Autor:
Jehan Dupuis, Philippe Gaulard, Francois Hemery, Emmanuel Itti, Christian Gisselbrecht, Alain Rahmouni, Christiane Copie-Bergman, Josette Brière, Taoufik El Gnaoui, Isabelle Gaillard, Michel Meignan, Corinne Haioun
Publikováno v:
Haematologica, Vol 92, Iss 6 (2007)
Background and Objectives Diffuse large B-cell lymphomas (DLBCL) have a variable outcome, and powerful methods of prognostication are needed in order to choose the best treatment for each patient. Immunophenotypic classification of the tumor as germi
Externí odkaz:
https://doaj.org/article/c4a3814757164c0bb88bbd5ec65a0a4f
Autor:
Simon B. Gressens, Slim Fourati, Anne Le Bouter, Fabien Le Bras, Jehan Dupuis, Mohammad Hammoud, Taoufik El Gnaoui, Romain Gounot, Louise Roulin, Karim Belhadj, Corinne Haioun, Sébastien Gallien, Giovanna Melica, François Lemonnier
Publikováno v:
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 28(6)
COVID-19 patients affected by haematological malignancies have a more severe course of the disease and higher mortality, prompting for effective prophylaxis. The present study aims to evaluate the humoral response after mRNA vaccination as well as th
Autor:
Philippe Gaulard, Hervé Tilly, Vincent Camus, Stéphanie Becker, Corinne Haioun, Fabien Le Bras, Louise Roulin, Clarisse Cazelles, François Lemonnier, Taoufik El Gnaoui, Elsa Poullot, Muriel verlinde Carvalho, Fabrice Jardin, Emmanuel Itti, Nicolas Mounier, Liana Veresezan, Hélène Vellemans, Karim Belhadj, Jehan Dupuis
Publikováno v:
Leukemia & lymphoma
Leukemia & lymphoma, Taylor & Francis, 2021, pp.1-8. ⟨10.1080/10428194.2021.1901090⟩
Leukemia & lymphoma, Vol. 62, no. 9, p. 2161-2168 (2021)
Leukemia & lymphoma, Taylor & Francis, 2021, pp.1-8. ⟨10.1080/10428194.2021.1901090⟩
Leukemia & lymphoma, Vol. 62, no. 9, p. 2161-2168 (2021)
International audience; There is no established standard treatment for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in patients who are not eligible to receive an intensive treatment. The combination of rituximab gemcitabine and ox
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::242a7b2f9f2d82afc0687064a3cdb85f
https://hal.archives-ouvertes.fr/hal-03226290
https://hal.archives-ouvertes.fr/hal-03226290
Autor:
Corinne Haioun, Philippe Gaulard, Louise Roulin, Christiane Copie Bergman, Thierry Jo Molina, Romain Gounot, Fabien Le Bras, Elsa Poullot, Cyrielle Robe, Paul Blanc-Durand, Sébastien Mulé, Marie Helene Delfau Larue, Taoufik El Gnaoui, François Lemonnier, Emmanuel Itti, Jehan Dupuis, Karim Belhadj, Mohammad Hammoud
Publikováno v:
Blood. 138:4576-4576
Background : High grade B cell lymphoma (HGBL) either Not Otherwise Specified (NOS) or either Double Hit (DH MYC/BCL2 or DH MYC/BCL6) or Triple Hit (TH) have been considered as separate entities from Diffuse Large B-Cell Lymphoma (DLBCL) NOS in the 2
Autor:
Sébastien Mulé, Alina Nicolae, Jehan Dupuis, Marie Helene Delfau Larue, Corinne Haioun, Cyrielle Robe, Karim Belhadj, Mohammad Hammoud, Jean-Philippe Jais, Louise Roulin, François Lemonnier, Fabien Le Bras, Asma Beldi-Ferchiou, Elsa Poullot, Taoufik El Gnaoui, Christiane Copie, Elodie Scherman, Emmanuel Itti, Philippe Gaulard, Alizée Maarek
Publikováno v:
Blood. 134:4122-4122
Introduction: Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogeneous disease characterized by recurrent genetic alterations. Several adverse prognostic factors are well known as International Prognostic Index (IPI) parameters or MYC
Autor:
Corinne Haioun, Michel Meignan, Alain Luciani, Emmanuel Itti, Chieh Lin, Eva Evangelista, Pauline Beaussart, Taoufik El-Gnaoui, Alexandre Vignaud, Karim Belhadj, Pierre Brugières, S. Lin, Alain Rahmouni
Publikováno v:
European Radiology. 20:2027-2038
To design a whole-body MR protocol using exclusively diffusion-weighted imaging (DWI) with respiratory gating and to assess its value for lesion detection and staging in patients with diffuse large B-cell lymphoma (DLBCL), with integrated FDG PET/CT
Autor:
Emmanuel Itti, François Hemery, Christiane Copie-Bergman, Taoufik El Gnaoui, Christian Gisselbrecht, Philippe Gaulard, Isabelle Gaillard, Josette Brière, Michel Meignan, Corinne Haioun, Alain Rahmouni, Jehan Dupuis
Publikováno v:
Haematologica. 92:778-783
Background and Objectives Diffuse large B-cell lymphomas (DLBCL) have a variable outcome, and powerful methods of prognostication are needed in order to choose the best treatment for each patient. Immunophenotypic classification of the tumor as germi
Autor:
Richard Delarue, Anne Sonet, Tony Petrella, Danièle Canioni, Gilles Salles, Corinne Haioun, Catherine Sebban, Nicolas Mounier, Pauline Beaussart, Serge Bologna, Taoufik El Gnaoui, Hervé Tilly, Rene-Olivier Casasnovas, Philippe Gaulard, Sylvie Castaigne, Alain Rahmouni
A previous pilot study with rituximab, gemcitabine and oxaliplatin showed promising activity in patients with refractory/relapsed B-cell lymphoma. We, therefore, conducted a phase II study to determine whether these results could be reproduced in a m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1a42e316f95f9a55292ce3d789d5045
https://europepmc.org/articles/PMC3815173/
https://europepmc.org/articles/PMC3815173/